[Pharmacogenetic test (Neurofarmagen®) to assess the potential response to drugs and adverse effects in patients with neuropsychiatric disorders]

Soto N, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L
Record ID 32015000881
Authors' recommendations: No evidence was found on the clinical usefulness of Neurofarmagen® in decision making related to neuropsychiatric disorders. There is moderate quality evidence on the potential relationship between some genes and the pharmacokinetic characteristics, effectiveness and adverse effect occurrence of those psychopharmacological drugs which are substrate or act through proteins encoded by these genes. However, there is still no evidence indicating that assessment of the genes included in Neurofarmagen® or any other test, would be of clinical benefit for these patients. Health sponsors only cover certain pharmacogenetic tests under specific conditions or consider them experimental.
Project Status: Completed
Year Published: 2015
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Genotype
  • Genetic Markers
  • Genome, Human
  • Mental Disorders
  • Neuropsychiatry
  • Antipsychotic Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.